Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC is a phase 2 interventional study registered as NCT05733598 by Replimune, Inc., with 60 participants planned, started 2024-08-01 and due to reach its primary completion in 2027-12-01. Interventions recorded: RP2, Bevacizumab, Atezolizumab, Durvalumab, RP2 Monotherapy. Conditions listed: Hepatocellular Carcinoma, Biliary Tract Cancer. No results are recorded here; the registry entry is the source.